MPN pathogenesis is promoted by mutually exclusive somatic “driver” mutations affecting three genes Janus kinase 2 (JAK2), MPL Proto-Oncogene or Thrombopoietin Receptor (MPL) and Calreticulin (CALR). Here, JAK2 is linked to myeloproliferative disorder.